Orphan Drug Investors Share Their Insights at RESI San Diego

11 May

By Lucy Parkinson, Director of Research, LSN

Orphan diseases present a unique opportunity for a biotech investor; faster development, market exclusivity and the possibility of delivering a cure to patients with no current treatment options. However, these small markets also present unique challenges in development and strategy.

At RESI San Diego, five experienced investors who specialize in rare disease opportunities will explain their strategies in the sector. These investors will explore how they identify potential in a rare disease therapeutic, and how they turn tiny markets into significant ROI.

Moderated by Ken Kengatharan, General Partner, Atheneos Capital, panelists include:

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: